Cannabis industry observers believe it is increasingly likely that President Donald Trump will soon sign an executive order directing federal agencies to complete the marijuana rescheduling process. But multiple reports indicate that the directive could also contain additional components touching on cannabis business banking access and Medicare coverage for CBD.

U.S. President Donald Trumphas signed an executive order demanding a speedy reclassification of marijuana that would ease federal restrictions on research that could lead to new medical marijuana products.

President Donald Trump on Thursday signed an executive order directing the U.S. Attorney General to accelerate the process of reclassifying marijuana under federal law, marking a significant shift in national drug policy while stopping short of full legalization.

Trump's executive order hastens a recategorization of marijuana from a Schedule I drug under the 1971 Controlled Substances Act to Schedule III.

As the world's population ages, the number of people living with dementias such as Alzheimer's disease increases.

President Trump signed an executive order reclassifying the federal status of marijuana, categorizing it as a drug with less potential for harm and dependence. It's a major shift in policy that could have wide-ranging effects on cannabis use and research.

A new study published in the Journal of Psychopharmacology suggests that older adults who frequently use cannabis experience specific acute declines in cognitive function, particularly in processing speed and executive functioning.

The most frequently reported reasons for medicinal cannabis use are for pain relief and improvements in sleep. Although cannabis is believed to have an interconnected role with both pain and sleep, its effects on chronic pain and sleep architecture have been studied largely in isolation.

President Trump weighs in on a debate between hard-liners on marijuana and those who want more research on its medical uses.

The order moves marijuana from Schedule I to the less restrictive Schedule III, grouping it with controlled medical substances like ketamine, steroids and some opioids.

Michigan's 24% tax on marijuana will go into effect at the start of 2026 after a Court of Claims judge denied a request for an injunction.

Such a decision would represent one of the ​most significant federal changes to marijuana policy in decades. It could reshape the cannabis industry, ease criminal penalties, unlock billions in research funding and lead to the opening ​of doors long closed ⁠to banks and investors.